CavoGene LifeSciences is a biotechnology company focused on the treatment of neurodegenerative diseases. It has expertise in the discovery, development and commercialization of gene therapies that attenuate memory loss and increase synaptic neuroplasticity. The company offers a gene therapy for the treatment of amyotrophic lateral sclerosis (ALS), colloquially known as Lou Gherig's disease, and other forms of neurodegeneration.